SEC Comment Letter 0000000000-24-013046 to Coya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc.
Date: Nov. 25, 2024 · CIK: 0001835022 · Accession: 0000000000-24-013046
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283366
Letter
November 25, 2024 Arun Swaminathan Chief Executive Officer Coya Therapeutics, Inc. 5850 San Felipe St. Suite 500 Houston, TX 77057 Re:Coya Therapeutics, Inc. Registration Statement on Form S-3 Filed November 20, 2024 File No. 333-283366 Dear Arun Swaminathan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Steven Skolnick, Esq.
Show Raw Text
November 25, 2024
Arun Swaminathan
Chief Executive Officer
Coya Therapeutics, Inc.
5850 San Felipe St. Suite 500
Houston, TX 77057
Re:Coya Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 20, 2024
File No. 333-283366
Dear Arun Swaminathan:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Steven Skolnick, Esq.